Kornimate/medical-research-clean huggingface dataset:
pain and perceptual distortion of face

Conditions: Neuropathic Pain; Orofacial Pain

Summary: post-traumatic trigeminal neuropathic pain (ptnp) is "a unilateral or bilateral facial or oral pain following and caused by trauma to the trigeminal nerve(s), with other symptoms and/or clinical signs of trigeminal nerve dysfunction, and persisting or recurring for more than 3 months". ptnp may result from a major craniofacial/oral trauma or may be subsequent to relatively minor dental treatments such as teeth extractions, surgeries, root canal treatment. patients suffering from this condition have a significantly reduced quality of life. unfortunately, the currently available management modalities are associated with limited success and side effects. repetitive transcranial magnetic stimulation (rtms), which is a safe, non-invasive brain stimulation technique has emerged as a potential treatment for chronic pain. in this study, the purpose is to explore the potential of rtms in treating the persistent neuropathic pain by providing individualized treatment for the sufferers.

in addition to pain, a curious observation in people with ptnp is that they report that the painful facial area is "swollen" or "feels differently". there are often no clinical signs or physical differences present, hence such self-reported "illusions" may represent a kind of disrupted body image or a "perceptual distortion" of the face and can be speculated to contribute to the maintenance of facial pain. rtms paradigms are being widely applied in both therapeutic and investigative studies.in this project, the aim is to employ continuous theta-burst stimulation (ctbs), an inhibitory rtms paradigm, to evaluate its effect on pain perception and pd in people with ptnp. in this project, people with ptnp (n=9) received a rtms (50 hz, 600 pulses for 40s) session/week as intervention for four consecutive weeks at the primary somatosensory cortex (face area) in a "n-of-1" single-blinded randomized controlled cross-over design: (a) active-sham-active-sham or (b) sham-active-sham-active. that is the same participant received both active and sham either in the (a) order or (b). pain intensity and perceptual distortion (pd) as perceived size changes of the affected face area were measured at baseline, immediately, 60 mins after rtms in each session and end of the session (a week after rtms), one and three months after rtms. questionnaires on quality of life, jaw function, sleep quality were also assessed. changes in pain and pd after each intervention were evaluated.

Eligibility criteria:
inclusion criteria: * persistent post-traumatic trigeminal neuropathic pain patients for 6 months or longer * stable on analgesic medication exclusion criteria: * past history of tms therapy or tms-related contraindications (pacemaker, epilepsy etc.). * major stroke * pregnancy * severe organic brain damage

Keywords: repetitive transcranial magnetic stimulation n-of-1 trials perceptual distortion post-traumatic trigeminal neuropathic pain
prospective observational correlation of sperm assay results with blastocyst formation

Conditions: Infertility

Summary: we will investigate potential correlation between spermcomet dna fragmentation assay results and ivf cycle outcome.

a "spermcomet" assay will be used to characterize dna fragmentation of surplus sperm samples remaining after in vitro fertilization (ivf) cycles. we will investigate potential correlation between these assay results and the outcomes of ivf cycles that used those sperm samples.

Eligibility criteria:
inclusion criteria: * undergoing ivf * surplus sperm available after oocyte insemination * consented exclusion criteria: * surgical sperm extraction * use of donated sperm or oocytes * no minors may participate
epo deep tank in dialysis subjects

Conditions: Chronic Kidney Disease

Summary: subject incidence of adverse events

to determine whether epoetin alfa manufactured by a roller bottle technology (epoetin alfa rb) and epoetin alfa manufactured by a deep tank process (epoetin alfa dt) have comparable safety profiles when administered to patients with ckd receiving dialysis.

Eligibility criteria:
inclusion criteria: - ≥ 18 years of age - receiving hemodialysis or peritoneal dialysis - baseline hb between 11.0 g/dl and 13.0 g/dl - currently receiving epoetin alfa rb ie. epogen or procrit - transferrin saturation (tsat) \>15.0% exclusion criteria: - currently receiving or ever received treatment with any erythropoietic stimulating protein other than epogen, procrit and aranesp. - uncontrolled hypertension (defined as diastolic blood pressure \>110 mmhg or systolic bp \>180 mmhg during screening). - grand mal seizure within the last 6 months prior to screening. - acute myocardial ischemia; hospitalization for congestive heart failure or myocardial infarction within 12 weeks before enrollment. - stroke (hemorrhagic or ischemic) or transient ischemic attack within 12 weeks before enrollment. - major surgery within 3 months prior to screening (excluding vascular access surgery). - clinical evidence of systemic infection or inflammatory disease at the time of screening and up until enrollment. for peritoneal dialysis subjects, an episode of peritonitis within 30 days before screening. - known positivity for hiv antibody or hepatitis b surface antigen. clinical evidence of current malignancy with the exception of basal cell or squamous cell carcinoma of the skin. - blood transfusions within 8 weeks prior to screening or active bleeding. - androgen therapy within 8 weeks prior to screening. systemic hematological disease (eg ,sickle cell anemia, myelodysplastic syndromes, hematological malignancy); myeloma; hemolytic anemia. - other investigational products are excluded. - subject is currently enrolled in, or has not yet completed, a period of at least 30 days since ending other investigational device or drug trial(s). psychiatric, addictive, or any other disorder that compromises ability to give truly informed consent for participation in this study. - pregnant or breast feeding (women of child-bearing potential must be taking adequate contraceptive precautions). - anticipating or scheduled for a living-related kidney transplant. - known history of severe hyperparathyroidism (pth \>1500pg/ml) within 3 months prior top enrollment. - currently receiving home hemodialysis treatment. - currently receiving immunosuppressive therapy.

Keywords: epogen procrit chronic kidney disease anemia treatment for dialysis patients
efficacy study of diacerein on glycemic control and liver fat in type 2 diabetes subjects

Conditions: Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease

Summary: this study is conducted to test the hypothesis that in uncontrolled type 2 diabetic adults treatment with diacerein will improve glycemic control and will reduce liver fat within a 24 month period.

background: recently, knowledge about diacerhein, an anthraquinone drug with powerful anti-inflammatory properties, revealed that this drug improves insulin sensitivity, mediated by the reversal of chronic subclinical inflammation. amongst the numerous pathogenetic factors, oxidative stress and apoptosis of hepatocytes initiate many inflammatory processes and are involved in the progression of non alcoholic fatty liver disease. aims:the aim is to evaluate the effect of treatment with diacerein in improvement of glycemic parameters (mean glycated hemoglobin, fasting blood sugar) and reduction of liver fat fraction. methods:two-hundred patients will be randomly allocated either to treatment with diacerein plus their usual therapeutic regimen or to placebo for 24 months. clinic, laboratory evaluation (including glycated hemoglobin, fasting blood sugar, creatinine, ferritin, aspartate aminotransferase (ast), alanine aminotransferase (alt), g-glutamyl transpeptidase, alkaline phosphatase, bilirubin, albumin, prothrombin time, platelet count, total cholesterol, high-density and low-density lipoprotein cholesterol and triglycerides and urinary albumin excretion rate no 24-hour urine collection) will be performed before and every 3 months until the end of study. pro-inflammatory cytokines, adiponectin and cytokeratin-18 were measured before, at 12 months and at the end of study. liver fat fraction measurement using controlled attenuation parameter (cap) by transient elastography. (fibroscan) will be performed before and after the 12 and 24-month treatment, with the observers blinded to the allocation group.

Eligibility criteria:
inclusion criteria: * type 2 diabetes. * presence of liver steatosis diagnosed by ultrasound or transient elastography (fibroscan®) * age 30-75 years. * hba1c 7.5- 9.5 for at least 8 weeks prior to screening. * stable diabetes therapeutic regimen consisting of either diet, oral hypoglycemic agents with or without insulin for 8 weeks prior to randomization. exclusion criteria: * body mass index \> 40 kg/m2 * serum creatinine ≥180mmol/l or estimated glomerular filtration rate \< 30 ml/min. * presence of any serious concomitant disease, such as a pulmonary disease or malignant disorders. * current daily alcohol ingestion ≥20 g. * hepatotoxic drugs. * presence of other chronic liver disease other than nonalcoholic fatty liver disease, including hepatitis b virus and hepatitis c virus infection, hemochromatosis, wilson's disease, alfa-1 antitrypsin deficiency, autoimmune hepatitis. * women seeking pregnancy. * current use or previous use within 6 months of vitamin e or pioglitazone

Keywords: fat liver diabetes diacerein transient elastography treatment
esthetic, clinical and radiographic outcomes of immediate and delayed implant placement

Conditions: Jaw, Edentulous, Partially; Acquired Absence of Single Tooth

Summary: the aim of this prospective cohort study is to compare the esthetic, clinical and patient-centered outcomes following immediate and delayed implant placement protocols.

patients are divided into two groups: immediate and delayed implant placement. the investigators are asking subjects to take part in a research study of soft tissue and bone healing around dental implants following tooth extraction. the investigators want to compare how the gums and the bone changes shape with healing in two different scenarios.

Eligibility criteria:
inclusion criteria: * at least 18 years old and able to understand an informed consent * adequate oral hygiene to allow for implant therapy consistent with standards of care. * missing a single tooth in the maxillary anterior region * presence of adjacent natural teeth exclusion criteria: * poor oral hygiene * severe parafunctional habits, for example, bruxing and clenching * presence of clinically active periodontal disease as expressed by probing pocket depths≥4 mm in combination with bleeding on probing. * conditions that might lead to a possibly lowered regenerative capacity of the bone, for example, osteoporosis and paget's disease * pregnant or expecting to be pregnant * history of drug and alcohol abuse * history of systemic diseases that would contraindicate oral surgical treatment, for example, uncontrolled diabetes (defined as hba1c level \>7%) * radiotherapy in the head and neck area, * on certain medications like bisphosphonates or steroids currently or within the past three months * absence of adjacent teeth * unwillingness to return for the follow-up examination * smokers (more than 20 cigarettes per day). subjects smoking \<20 cigarettes per day were requested to stop smoking before and after surgery

Keywords: delayed implant esthetics immediate implant bone augmentation
freiburg zns-nhl study

Conditions: Primary Non Hodgkin Lymphoma of the Central Nervous System

Summary: the purpose of this study is to determine whether combined chemotherapy \[rituximab plus high dosage methotrexate (max. 2 cycles) followed by arabinoside/thiotepa (max. 2 cycles) followed by high dosage carmustin/thiotepa\] followed by peripheral blood stem cell transplantation is effective in the treatment of cerebral non hodgkin lymphoma \[pcnsl\].


Eligibility criteria:
inclusion criteria: * group a: first diagnosis of pcnsl, histologically confirmed * group b: relapse or progression of pcnsl after mtx containing chemotherapy * age 18 - 65 years * not legally incompetent, physically or mentally incapable of giving consent * written signed and dated informed consent of the legal representative and - if possible - of the patient exclusion criteria: * manifestations of further lymphoma outside the cns * sero-positive for hiv * severe pulmonary, cardiac, hepatic, renal impairment * neutrophil count \< 2.000/µl, platelet count \< 100.000/µl * pulmonary disease with ivc \< 55%, dlco \< 40% * cardiac ejection fraction \< 50%, uncontrolled malign arrhythmia * creatinine \> 1,5 mg% or creatinine-clearance \< 50ml/min * bilirubin \> 2mg/dl * ascites or pleural effusion (\> 500ml) * pregnancy o r lactation * women with childbearing potential without sufficient contraception * participation in another clinical trial within the last 30 days prior to the begin or parallel to this study * known or current drug or alcohol abuse * known hypersensitivity against methotrexate, cytarabine, thiotepa, bcnu rituximab, leukovorin, dexamethasone, neupogen and neulasta.
rapid build of hiv related protective barriers

Conditions: Viral Suppression of HIV Infection

Summary: the purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against hiv-infection by maximally decreasing the viremia among hiv- infected patients.

sexual transmission became the primary route of hiv transmission in china and heterosexual transmission also contributed greatly to hiv epidemic which was mostly reported in south-west rural areas. in past years, yunnan has experienced powerful campaign of scaling-up the hiv identification as well as antrertroviral therapy. this study will investigate how to reach the last two of hiv'90-90-90 targets': to provide antiretroviral therapy (art) for 90% of who diagnosed hiv infection and to achieve viral suppression for 90% of those treated. the study population consists of participants who received an newly diagnosed hiv infection within the study period. all rerolled participants will be randomized into different study group. in intervention group, medical institutions will provide patients personal involved intervention strategies which guided by frequent viral load detection, and providing of the dosage form of 400 mg efv in their antiviral therapy. main assessment measures are viral suppression rate of hiv-infected patients and treatment coverage .

Eligibility criteria:
inclusion criteria: * hiv-positive participants who received an newly diagnosed hiv infection within the study period * having a current residential address inside of pilot site limits * eighteen years old or above * hiv transmission is heterosexual contact exclusion criteria: * idu * having severe mental disorder
tooth discoloration induced by pulpotomy materials

Conditions: Tooth Discoloration

Summary: vital pulp therapy including pulpotomy is commonly used for managing teeth with carious pulp exposure instead of performing root canal therapy. the gold standard materials used in this procedure are the calcium silicate based materials, however recent case reports have shown tooth discoloration caused by these materials especially mta which is of concern to the patients. the aim of this study is to compare tooth color changes and discoloration induced by 3 calcium silicate based materials used in pulpotomy over 6 months, 12 months and yearly up to 5 years.

pulpotomy procedure involves removal of the coronal portion of the dental pulp followed by placement of a compatible material and subsequent coronal restoration of the tooth. mineral trioxide aggregate is the gold standard material used in pulpotomy; however it has been implicated in tooth discoloration due to it radioopacifier. newer calcium silicate based materials including biodentine and bioceramic have different opacifier and claimed not to cause tooth discoloration in laboratory studies. in this clinical study tooth color measurement of teeth treated by pulpotomy using these 3 materials will be taken using vita easy shade device immediately after placement of the materials, 6 months and 12 months after the treatment then yearly up to 5 years. the discoloration potential of these 3 materials will be compared. factors that may influence tooth discoloration will be also measured and analyzed including buccal wall thickness and time of bleeding control after pulpotomy.

Eligibility criteria:
inclusion criteria: * vital tooth with carious pulp exposure to be treated by full pulpotomy * fully erupted upper or lower molar tooth with fully formed apex * tooth should have intact buccal wall (no caries or restoration) * tooth should be restorable by direct composite restoration exclusion criteria: * partially erupted tooth * tooth has caries on the buccal surface * tooth has restoration on buccal surface * tooth has preoperative coronal staining compared to adjacent teeth

Keywords: pulpotomy, mta, biodentine, bioceramic, discoloration
confidential care and adolescent hiv testing

Conditions: Hiv

Summary: the purpose of this study is to assess the feasibility and acceptability of structural intervention components to increase adolescent hiv testing uptake by improving the implementation of confidential care as standard practice in pediatric primary care.

this pilot study will evaluate a multicomponent structural intervention to increase adolescent hiv testing uptake by improving the implementation of confidential care as standard practice in pediatric primary care settings. the objectives of the study are to: (a) evaluate feasibility, acceptability, and other implementation outcomes (e.g., reach); (b) assess change in hiv testing uptake; and (c) determine the combination of structural intervention components to be further evaluated in a future full-scale optimization trial. these objectives will be achieved through a pilot optimization trial; the trial will follow a full factorial experimental design with data collection at three time points over a 12-month period. during the 6-month pre-intervention period, baseline measures will be assessed extracting electronic health record (ehr) data on the number of adolescent patients who were screened for, accepted, and received results of hiv testing. during the 6-month intervention period, clinics will be randomized to one of four experimental conditions based on the following two factors: (1) provider training; (2) implementation of clinic protocols to support confidential care provision. clinics randomized to a condition involving provider training will receive training on state-specific laws regulating minors' access to confidential hiv testing. clinics randomized to a condition involving the implementation of clinic protocols will receive training on navigating the new protocols. measurement of intervention and implementation processes and outcomes will be guided by the five dimensions of the re-aim framework: reach, efficacy, adoption, implementation, and maintenance. during the 6-month post-intervention period, ehr data will be used to assess the change in hiv testing uptake over the study period.

Eligibility criteria:
the intervention occurs at the clinic-level and so the enrolled participant is a pediatric primary care clinic. the patient-level outcome (i.e., change in hiv testing uptake) will be collected based on the following eligibility criteria: inclusion criteria: - 13-17 years old exclusion criteria: * \<13 years old * \>17 years old

Keywords: confidential care pediatrics hiv testing
fs-1 drug for treatment of multiple drug-resistant tuberculosis

Conditions: Tuberculosis, MDR

Summary: drug-resistant tuberculosis is becoming a major problem for the whole humanity, and development of new anti-tb drugs is of great importance. since kazakhstan is a country with the high burden of tuberculosis, the government of the republic of kazakhstan has founded initiative on the development of new anti-tb drug to treat drug-resistant forms of this infectious disease. jsc "scientific center for anti-infectious drugs" has developed original drug fs-1 for the treatment of multidrug resistant tuberculosis (mdr-tb).

phase 3 clinical study of fs-1 drug is a randomized, interventional, multicenter, placebo-controlled (add-on), double-blind and two arms trial. the study consists of two following phases: treatment phase - 6 months and follow-up phase 12 months. it is planned to recruit 480 patients with verified mdr-tb diagnosis. all data will be compiled in an electronic data capture system with further statistical analysis according to approved statistical analytical plan.

Eligibility criteria:
inclusion criteria: * subjects suffering from a multidrug-resistant form of pulmonary tuberculosis which is defined by: * mdr tuberculosis confirmed by microbiology test at screening. * resistance to isoniazid and rifampicin demonstrated by drug susceptibility test * susceptiblity of tb bacteria to fluoroquinolones and aminoglycoside/capreomycin * all ethnicities, intellectually capable of understanding their own condition and the requirements of the study protocol * willing to freely and voluntarily give signed informed consent * willing and capable to comply with all requirements of the protocol exclusion criteria: * pregnancy and breast-feeding; * patients with decompensated concomitant diseases (cardiovascular, renal, hepatic failure) that may affect the conduct of the study; * severe mental disorders; * allergy to iodine-containing drugs, hypersensitivity to iodine; * intolerance to second-line drugs; * epidermomycosis * socially maladjusted patients suffering from alcoholism and drug addiction; * hypothyroidism; * hashimoto's thyroiditis; * tb treatment for more than two months before the start of the study; * not willing to adhere to tb therapy; exclusion criteria during the study: * at the discretion of the researcher, if the continuation of the study is harmful to the patient; * side effects related with the study drug * patient's decision to stop participation in study * appearance of any exclusion criteria during study

Keywords: tuberculosis multi-drug resistant tb tb treatment
risk of chronic post-surgical pain after tka

Conditions: Bilateral Total Knee Chronic Pain Following Arthroplasty

Summary: chronic post-surgical pain (cpsp) is a common surgical complication. the role of timing in the development of cpsp after bilateral total knee arthroplasty (btka) is not well studied. we aimed to compare the occurrence of cpsp in patients who underwent simultaneous or staged btka without discharge between procedures.


Eligibility criteria:
inclusion criteria: * from october 12, 2012 to december 2, 2021, patients who underwent bilateral or staged knee replacement surgery during a single hospitalization under professor lee woo-seok at the department of orthopedics at gangnam severance hospital due to bilateral knee arthritis. exclusion criteria: * patients whose post-operative pain information cannot be confirmed through outpatient visit records 1 year after surgery * those who have undergone surgery other than knee arthritis surgery within 1 year after surgery